Kymera Therapeutics posts corporate deck outlining push to develop oral targeted protein degraders for immunology

PUBT · 1d ago
Kymera Therapeutics posts corporate deck outlining push to develop oral targeted protein degraders for immunology
  • Kymera outlined a strategy to commercialize oral targeted protein degraders in immunology, aiming to match biologics-like activity with pill convenience.
  • Lead asset KT-621, an oral STAT6 degrader, positioned for dupilumab-like efficacy across Type 2 inflammatory diseases; Phase 2b atopic dermatitis data due by year-end 2026.
  • Phase 3 atopic dermatitis trials planned to start by mid-2027; Phase 2b asthma readout targeted for late 2027.
  • Second wholly owned program KT-579, an IRF5 degrader, targets lupus and related autoimmune diseases; Phase 1 healthy-volunteer data expected in 4Q26.
  • Partnered pipeline includes KT-485, an IRAK4 degrader with an IND targeted for 2027, alongside KT-200, a CDK2 degrader for solid tumors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.